Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Barclays PLC

Barclays PLC lowered its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 69.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 370,894 shares of the company's stock after selling 846,137 shares during the quarter. Barclays PLC owned about 0.30% of Guardant Health worth $11,333,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GH. R Squared Ltd purchased a new stake in shares of Guardant Health during the 4th quarter valued at about $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $43,000. Kimelman & Baird LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $58,000. Quantbot Technologies LP purchased a new position in shares of Guardant Health in the 4th quarter worth approximately $80,000. Finally, Jones Financial Companies Lllp increased its position in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler raised their price target on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Raymond James reaffirmed an "outperform" rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. The Goldman Sachs Group lifted their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Stifel Nicolaus increased their target price on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Morgan Stanley lifted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Twenty research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $49.00.

Guardant Health Stock Up 1.9 %

Shares of GH traded up $0.89 during mid-day trading on Friday, reaching $48.30. The company had a trading volume of 1,405,230 shares, compared to its average volume of 2,139,091. Guardant Health, Inc. has a 52-week low of $16.77 and a 52-week high of $50.89. The stock has a market capitalization of $5.96 billion, a P/E ratio of -13.57 and a beta of 1.45. The stock has a 50 day moving average of $43.37 and a two-hundred day moving average of $37.19.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. On average, sell-side analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.